Format

Send to

Choose Destination
Transfus Apher Sci. 2017 Apr;56(2):179-189. doi: 10.1016/j.transci.2016.11.004. Epub 2016 Nov 30.

Quantifying in vivo murine antigen-specific T cell responses without requirement for prior knowledge of antigen identity.

Author information

1
Department of Dermatology, Yale School of Medicine, United States.
2
Department of Biomedical Engineering, Yale School of Medicine, United States.
3
Department of Biomedical Engineering, Yale School of Medicine, United States; Department of Immunobiology, Yale School of Medicine, United States.
4
Department of Dermatology, Yale School of Medicine, United States. Electronic address: redelson@yale.edu.

Abstract

Extracorporeal Photochemotherapy (ECP) is a widely applied anti-cancer immunotherapy for patients with cutaneous T cell lymphoma (CTCL). By using apoptotic malignant cells as a source of patient-specific tumor antigen, it enables clinically relevant and curative anti-CTCL immunity, with potential efficacy in other tumors. Currentmethods to track patient-specific responses are tedious, and new methods are needed to assess putative global immunity. We developed a clinically practical method to assess antigen-specific T cell activation that does not rely on knowledge of the particular antigen, thereby eliminating the requirement for patient-specific reagents. In the OT-I transgenic murine system, we quantified calcium flux to reveal early T cell engagement by antigen presenting cells constitutively displaying a model antigenic peptide, ovalbumin (OVA)-derived SIINFEKL. We detected calcium flux in OVA-specific T cells, triggered by specific T cell receptor engagement by SIINFEKL peptide-loaded DC. This approach led to sensitive detection of antigen-specific calcium flux (ACF) down to a peptide-loading concentration of ∼10-3uM and at a frequency of ∼0.1% OT-I cells among wild-type (WT), non-responding cells. Antigen-specific T cells were detected in spleen, lymph nodes, and peripheral blood after adoptive transfer into control recipient mice. Methods like this for assessing therapeutic response are lacking in patients currently on immune-based therapies, such as ECP, where assessment of clinical response is made by delayed measurement of the size of the malignant clone. These findings suggest an early, practical way to measure therapeutically-induced anti-tumor responses in ECP-treated patients that have been immunized against their malignant cells.

KEYWORDS:

Anti-tumor responses; Antigen-specific activation; Calcium flux; Early T cell signal

PMID:
28007431
DOI:
10.1016/j.transci.2016.11.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center